Company Overview of BIND Therapeutics, Inc.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specific pharmaceutical characteristics intended to target tumors at tissue, cellular, and molecular levels and to result in superior patient outcomes by enhancing the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. The company’s lead drug candidate includes BIND-014, a prostate-specific membrane antigen (PSMA) targeted Accurin that contains docetaxel, which is in Phase II clinical trials for non-small cell lung cancer. It is also developing BIND-510, a ...
325 Vassar Street
Cambridge, MA 02139
Founded in 2006
Key Executives for BIND Therapeutics, Inc.
BIND Therapeutics, Inc. does not have any Key Executives recorded.
BIND Therapeutics, Inc. Key Developments
BIND Therapeutics, Inc. Announces Extension of Global Collaboration with Pfizer Inc. to Develop and Commercialize Multiple Accurins
Apr 3 15
BIND Therapeutics, Inc. announced an extension of the terms of its global collaboration with Pfizer Inc. to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer's pipeline. The collaboration was originally established in April 2013 and the timeline for Pfizer to exercise its option to acquire the exclusive license for the first program continues to be September 2015. Both companies agreed to an extension of the timeline for the second program through March 2016.
BIND Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014
Mar 11 15
BIND Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $3,037,000 against $2,070,000 a year ago. Loss from operations was $9,180,000 against $8,033,000 a year ago. Net loss attributable to common stockholders was $8,494,000 or $0.51 per basic and diluted share against $8,077,000 or $0.50 per basic and diluted share a year ago. The year-over-year increase in revenue was primarily due to higher reimbursable research and development activities, primarily for AstraZeneca collaboration.
For the year, the company reported revenue of $10,426,000 against $10,901,000 a year ago. Loss from operations was $33,508,000 against $26,863,000 a year ago. Net loss attributable to common stockholders was $32,537,000 or $1.97 per basic and diluted share against $31,367,000 or $5.19 per basic and diluted share a year ago. The year-over-year decrease in revenue was primarily due to a reduction in up-front license fee revenue recognized that was partially offset by an increase in reimbursable research and development activities performed under collaboration agreements, principally for AstraZeneca, Pfizer and Roche.
BIND Therapeutics, Inc. Announces Executive Changes
Mar 10 15
BIND Therapeutics, Inc. announced that Andrew Hirsch has been appointed the acting president and chief executive officer of the company. Mr. Hirsch was formerly BIND’s chief operating officer and chief financial officer and replaces Scott Minick, who will remain a member of BIND’s Board of Directors. Prior to joining BIND, Mr. Hirsch was chief financial officer at Avila Therapeutics until its acquisition by Celgene, Inc., in March 2012. Previously, Mr. Hirsch served in roles of increasing responsibility during his nearly 10 year tenure at Biogen Idec, most recently as vice president, Corporate Strategy and M&A, where he played a key role in evaluating new strategies for the company and identifying strategic M&A opportunities. Key additions to the BIND scientific leadership team: Margaret Read, has joined BIND as vice president, Biology. In this position, Dr. Read will play a key role in defining strategic direction for the company’s Accurin product portfolio. Dr. Read has worked as a consultant with BIND for the past year and was formerly vice president, Product Development, at Infinity Pharmaceuticals. Prior to Infinity, Dr. Read was director of Cell and Molecular Oncology at Millennium. David Mantus, has joined BIND as vice president, Regulatory Affairs and Quality Assurance. Dr. Mantus will be responsible for the development and implementation of BIND’s regulatory strategy and lead all interactions with healthcare regulatory authorities. Dr. Mantus was formerly vice president, Regulatory Affairs, at Cubist Pharmaceuticals. Key organizational changes: Dan Koerwer has been appointed chief business officer. In this capacity, Mr. Koerwer will be responsible for business development, commercialization and program and alliance management. Mr. Koerwer joined BIND in 2010 as head of Business Development and was most recently senior vice president, Business Development and Commercial. In this role, he successfully led the creation of key strategic collaborations with AstraZeneca, Pfizer, Merck, Roche and Amgen. Mr. Koerwer is a member of the executive leadership team. Hagop Youssoufian, who joined BIND as chief medical officer in 2014, will continue to lead the company’s clinical development programs and will take on added responsibility for Regulatory Affairs and Quality Assurance at BIND in anticipation of advancing BIND-014 into phase 3 pivotal trials. Dr. Youssoufian will continue as a member of BIND’s executive leadership team. Chris Lindblom has been promoted to senior vice president, Finance and Administration. In his new role, he will manage operating performance and financing activities, as well as join the executive leadership team. Mr. Lindblom joined BIND in 2014 as vice president, Finance. He previously worked as vice president of Finance and Treasurer at OvaScience and held roles with increasing responsibilities, including vice president of accounting and financial planning, at Infinity Pharmaceuticals.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|